EverPoint Asset Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

EverPoint Asset Management’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-20,000	Closed	-$2.3M	–	667
2014 Q4	$2.3M	Buy	20,000 +5,000	+33%	+$606K	0.05%	353
2014 Q3	$2.34M	Sell	15,000 -115,000	-88%	-$16.7M	0.05%	339
2014 Q2	$16M	Buy	+130,000	New	+$14.4M	0.33%	74

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EverPoint Asset Management's SLXP Position: Q1 2015 in Review

EverPoint Asset Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 20,000 shares — an estimated $2.3M sold.

EverPoint Asset Management first reported a position in SLXP in Q2 2014 and held it in 3 quarters. The position peaked at $16M in Q2 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

EverPoint Asset Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
EverPoint Asset Management sold 20,000 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $2.3M.
EverPoint Asset Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2014 and held it in 3 quarters.
EverPoint Asset Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $16M in Q2 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on EverPoint Asset Management's 13F filing for Q1 2015, filed 15 May 2015.